Initial management and follow-up of differentiated thyroid cancer in children

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 11, 2010, Pages 1289-1300

  Waguespack, Steven G ^a   Francis, Gary ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Childhood; Follicular; Papillary; Pediatric; Thyroid carcinoma

Indexed keywords

IODINE 123; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROTROPIN;

ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SURVEILLANCE; DISTANT METASTASIS; ECHOGRAPHY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; REVIEW; RISK FACTOR; SECOND CANCER; THORAX RADIOGRAPHY; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION;

EID: 78951471320     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0095     Document Type: Review

References (115)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009.
2. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed October 6, 2010.
3. Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156:167-172.
4. Waguespack S, Wells S, Ross J, Bleyer A. Thyroid cancer. In: Bleyer A, O'Leary M, Barr R, Ries L, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival 1975-2000. Vol. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006:143-154.
5. Demidchik YE, Saenko VA, Yamashita S. Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. Arq Bras Endocrinol Metabol 2007;51:748-762.
6. Wu XC, Chen VW, Steele B, et al. Cancer incidence in adolescents and young adults in the United States, 1992-1997. J Adolesc Health 2003;32:405-415.
7. Spoudeas HA, ed. Paediatric endocrine tumours. A multi-disciplinary consensus statement of best practice from a working group convened under the auspices of the the British Society of Paediatric Endocrinology & Diabetes and the United Kingdom Children's Cancer Study Group. West Sussex, United Kingdom: Novo Nordisk Ltd; 2005.
8. Halac I, Zimmerman D. Thyroid nodules and cancers in children. Endocrinol Metab Clin North Am 2005;34:725-744.
9. Harness JK, Thompson NW, McLeod MK, et al. Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992;16:547-553.
10. Demidchik YE, Demidchik EP, Reiners C, et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 2006;243:525-532.
11. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours, Volume 8. Lyon, France: IARC Press; 2004.
12. Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br J Cancer 1995;72:777-783.
13. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 1988;104:1157-1166.
14. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well- differentiated nonmedullary thyroid cancer: a review. Thyroid 2002;12:683-702.
15. Borson-Chazot F, Causeret S, Lifante JC, et al. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J Surg 2004;28:1088-1092.
16. Schneider AB. Radiation-induced thyroid cancer. Available at: http://www.uptodate.com/patients/content/topic.do?topicKey=~dyVVqDEHRC2tDW. Accessed October 6, 2010.
17. Tucker MA, Jones PH, Boice JD Jr, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991;51:2885-2888.
18. Schlumberger M, Pacini F. Thyroid Tumors. Paris, France: Nucleon; 2003.
19. Faggiano A, Coulot J, Bellon N, et al. Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. J Nucl Med 2004;45:232-237.
20. Naing S, Collins BJ, Schneider AB. Clinical behavior of radiation-induced thyroid cancer: factors related to recurrence. Thyroid 2009;19:479-485.
21. Sobrinho-Simoes M, Maximo V, Rocha AS, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 2008;37:333-362.
22. Woyach J, Shah M. New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 2009;16:715-731.
23. Yamashita S, Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:422-429.
24. Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg 2008;32:678-682.
25. Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000;128:1043-1051.
26. Welch Dinauer CA, Tuttle RM, Robie DK, et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 1998;49:619-628.
27. Feinmesser R, Lubin E, Segal K, Noyek A. Carcinoma of the thyroid in children - a review. J Pediatr Endocrinol Metab 1997;10:561-568.
28. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341-343.
29. Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993;71:1348-1352.
30. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
31. Tuttle RM, Ball DW, Byrd D, et al. NCCN clinical practice guidelines in oncology: thyroid carcinoma, version 1, 2010. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/thyroid.pdf. Accessed October 6, 2010.
32. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202-220.
33. Guidelines for the Management of Thyroid Cancer, 2nd ed. London, United Kingdom: Royal College of Physicians; 2007.
34. Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer 2006;13:427-453.
35. Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.
36. Wada N, Sugino K, Mimura T, et al. Pediatric differentiated thy roid carcinoma in stage I: risk factor analysis for disease free survival. BMC Cancer 2009;9:306.
37. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:1088-1094.
38. Bal CS, Kumar A, Chandra P, et al. Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid 2004;14:217-225.
39. O'Gorman CS, Hamilton J, Rachmiel M, et al. Thyroid cancer in childhood: a retrospective review of childhood course. Thyroid 2010;20:375-380.
40. Hay ID, Gonzalez-Losada T, Reinalda MS, et al. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 2010;34:1192-1202.
41. Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck 1998;20:549-555.
42. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379.
43. Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320-325.
44. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-954.
45. Lang BH, Chow SM, Lo CY, et al. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg 2007;246:114-121.
46. Grubbs EG, Rich TA, Li G, et al. Recent advances in thyroid cancer. Curr Probl Surg 2008;45:156-250.
47. Powers PA, Dinauer CA, Tuttle RM, Francis GL. The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 2004;17:339-343.
48. Shaha AR. TNM classification of thyroid carcinoma. World J Surg 2007;31:879-887.
49. Wada N, Sugino K, Mimura T, et al. Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. Ann Surg Oncol 2009;16:3442-3449.
50. La Quaglia MP, Black T, Holcomb GW III, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 2000;35:955-959; discussion 960.
51. Landau D, Vini L, A'Hern R, Harmer C. Thyroid cancer in children: the Royal Marsden Hospital experience. Eur J Cancer 2000;36:214-220.
52. Brink JS, van Heerden JA, McIver B, et al. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery 2000;128:881-886; discussion 886-887.
53. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-2899.
54. Patel A, Jhiang S, Dogra S, et al. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatr Res 2002;52:737-744.
55. Lee YM, Lo CY, Lam KY, et al. Well-differentiated thyroid carcinoma in Hong Kong Chinese patients under 21 years of age: a 35-year experience. J Am Coll Surg 2002;194:711-716.
56. Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br J Cancer 1995;72:777-783.
57. Bal CS, Padhy AK, Kumar A. Clinical features of differentiated thyroid carcinoma in children and adolescents from a sub-Himalayan iodine-deficient endemic zone. Nucl Med Commun 2001;22:881-887.
58. Lazar L, Lebenthal Y, Steinmetz A, et al. Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr 2009;154:708-714.
59. Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008;93:3058-3065.
60. Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 2004;28:1187-1198.
61. Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: who is operating on our children? Surgery 2008;144:869-877; discussion 877.
62. Welch Dinauer CA, Tuttle RM, Robie DK, et al. Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. J Pediatr Surg 1999;34:1799-1804.
63. Jarzab B, Handkiewicz Junak D, Wloch J, et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 2000;27:833-841.
64. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-381.
65. Rachmiel M, Charron M, Gupta A, et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 2006;19:1377-1393.
66. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1057; discussion 1057-1058.
67. Shah MD, Hall FT, Eski SJ, et al. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003;113:2102-2107.
68. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-1501.
69. Demidchik IuE, Kontratovich VA. [Repeat surgery for recurrent thyroid cancer in children]. Vopr Onkol 2003;49:366-369 [in Russian].
70. Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. Ann Surg 1998;227:533-541.
71. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg 2003;69:191-196; discussion 196-197.
72. van Santen HM, Aronson DC, Vulsma T, et al. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur J Cancer 2004;40:1743-1751.
73. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
74. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-1242.
75. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457-480.
76. Chow S, Law S, Mendenhall W, et al. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 2004;42:176-183.
77. Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 2008;69:479-490.
78. Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 2008;68:610-617.
79. Meier DA, Brill DR, Becker DV, et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 2002;43:856-861.
80. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-515.
81. Dottorini ME, Vignati A, Mazzucchelli L, et al. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997;38:669-675.
82. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19:451-457.
83. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.
84. Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 2006;115:607-610.
85. Dinauer C, Francis GL. Thyroid cancer in children. Endocrinol Metab Clin North Am 2007;36:779-806.
86. Kuijt WJ, Huang SA. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab 2005;90:6123-6125.
87. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
88. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves shortterm clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-770.
89. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-654.
90. Lau WF, Zacharin MR, Waters K, et al. Management of paediat ric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J 2006;36:564-570.
91. Luster M, Handkiewicz-Junak D, Grossi A, et al. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab 2009;94:3948-3953.
92. Leboulleux S, Baudin E, Hartl DW, et al. Follicular cell-derived thyroid cancer in children. Horm Res 2005;63:145-151.
93. Reynolds JC. Comparison of I-131 absorbed radiation doses in children and adults: a tool for estimating therapeutic I-131 doses in children. In: Robbins JM, ed. Treatment of Thyroid Cancer in Childhood. Bethesda, MD: NIDDK, National Institutes of Health; 1992:127-135.
94. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-1591.
95. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer - the individual dosage of radioiodine. Endocr Relat Cancer 2010;17:R161-172.
96. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451-456.
97. Maxon HR. The role of radioiodine in the treatment of childhood thyroid cancer-a dosimetric approach. In: Robbins JM, ed. Treatment of Thyroid Cancer in Childhood. Bethesda, MD: NIDDK, National Institutes of Health; 1992:109-126.
98. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
99. Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med 1997;27:152-164.
100. Tuttle RM, Grewal RK, Larson SM. Radioactive iodine therapy in poorly differentiated thyroid cancer. Nat Clin Pract Oncol 2007;4:665-668.
101. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622-627. (Pubitemid 28480817)
102. Asari R, Koperek O, Scheuba C, et al. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg 2009;249:1023-1031.
103. Zou CC, Zhao ZY, Liang L. Childhood minimally invasive follicular carcinoma: clinical features and immunohistochemistry analysis. J Paediatr Child Health 2010;46:166-170.
104. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005;1:32-40.
105. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:1088-1094.
106. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441.
107. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-1111.
108. Bauer AJ, RM Tuttle, Francis G. Thyroid nodules and thyroid carcinoma in children. In: Pescovitz O, Eugster E, eds. Pediatric Endocrinology: Mechanisms, Manifestations, and Management. Philadelphia, PA: Lippincott, Inc; 2004.
109. LaQuaglia M, Black T, Holcomb G, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 2000;35:955-959.
110. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6553-6555.
111. Hoe FM, Charron M, Moshang T Jr. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 2006;19:25-30.
112. Antonelli A, Miccoli P, Fallahi P, et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 2003;13:479-484.
113. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531-1536.
114. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-1127.
115. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-351.